Organ- and species-specific biological activity of rosmarinic acid

Toxicology in Vitro

Volumn 32, Issue , 2016, Pages 261-268

  Iswandana, R ^a,b   Pham, B T ^a,c   van Haaften, W T ^a   Luangmonkong, T ^a,d   Oosterhuis, D ^a   Mutsaers, H A M ^a   Olinga, P ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF INDONESIA   (Indonesia)

^c HANOI UNIVERSITY OF PHARMACY   (Viet Nam)

^d MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Anti inflammatory; Antifibrotic; Precision cut intestinal slices; Precision cut liver slices; Rosmarinic acid; Toxicity

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; CXCL1 CHEMOKINE; FIBRONECTIN; HEAT SHOCK PROTEIN 47; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSMARINIC ACID; CINNAMIC ACID DERIVATIVE; CYTOKINE; DEPSIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL TISSUE; ANTIFIBROTIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; HUMAN; HUMAN TISSUE; INFLAMMATION; INTESTINE; LIVER FIBROSIS; LIVER SLICE; MALE; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; TISSUE CULTURE; ANIMAL; C57BL MOUSE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; IN VITRO STUDY; JEJUNUM; LIVER; LIVER CIRRHOSIS; METABOLISM; PATHOLOGY; SPECIES DIFFERENCE; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CINNAMATES; CYTOKINES; DEPSIDES; GENE EXPRESSION; HUMANS; IN VITRO TECHNIQUES; JEJUNUM; LIVER; LIVER CIRRHOSIS; MALE; MICE, INBRED C57BL; RATS, WISTAR; SPECIES SPECIFICITY;

EID: 84958238555     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2016.01.009     Document Type: Article

References (32)

1. Baba S., Osakabe N., Natsume M., Terao J. Orally administered rosmarinic acid is present as the conjugated and/or methylated forms in plasma, and is degraded and metabolized to conjugated forms of caffeic acid, ferulic acid and m-coumaric acid. Life Sci. 2004, 75:165-178. 10.1016/j.lfs.2003.11.028.
2. Baba S., et al. Absorption, metabolism, degradation and urinary excretion of rosmarinic acid after intake of Perilla frutescens extract in humans. Eur. J. Nutr. 2005, 44:1-9. 10.1007/s00394-004-0482-2.
3. Baumgart D.C., Carding S.R. Inflammatory bowel disease: cause and immunobiology. Lancet 2007, 369:1627-1640. 10.1016/S0140-6736(07)60750-8.
4. Bozic C.R., et al. The murine interleukin 8 type B receptor homologue and its ligands. Expression and biological characterization. J. Biol. Chem. 1994, 269:29355-29358.
5. Cheng A.-C., et al. Rosmanol potently induces apoptosis through both the mitochondrial apoptotic pathway and death receptor pathway in human colon adenocarcinoma COLO 205 cells. Food Chem. Toxicol. 2011, 49:485-493. 10.1016/j.fct.2010.11.030.
6. de Graaf I.a.M., et al. Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies. Nat. Protoc. 2010, 5:1540-1551. 10.1038/nprot.2010.111.
7. Domitrović R., et al. Rosmarinic acid ameliorates acute liver damage and fibrogenesis in carbon tetrachloride-intoxicated mice. Food Chem. Toxicol. 2013, 51:370-378. 10.1016/j.fct.2012.10.021.
8. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008, 134:1655-1669. 10.1053/j.gastro.2008.03.003.
9. Hossan S., Rahman S., Bashar A.B.M.A., Jahan R. Rosmarinic Acid : A Review of Its Anticancer Action 2014, 3:57-70.
10. Karmokar A., et al. Dietary intake of rosmarinic acid by Apc Min mice, a model of colorectal carcinogenesis: levels of parent agent in the target tissue and effect on adenoma development. Mol. Nutr. Food Res. 2012, 56:775-783. 10.1002/mnfr.201100617.
11. Krol W., et al. Inhibition of neutrophils' chemiluminescence by ethanol extract of propolis (EEP) and its phenolic components. J. Ethnopharmacol. 1996, 55:19-25. 10.1016/S0378-8741(96)01466-3.
12. Lee H.J., et al. Rosmarinic acid protects human dopaminergic neuronal cells against hydrogen peroxide-induced apoptosis. Toxicology 2008, 250:109-115. 10.1016/j.tox.2008.06.010.
13. Li G.-S., et al. In vitro and in vivo antifibrotic effects of rosmarinic acid on experimental liver fibrosis. Phytomedicine 2010, 17:282-288. 10.1016/j.phymed.2009.05.002.
14. Loftus E.V. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004, 126:1504-1517. 10.1053/j.gastro.2004.01.063.
15. Mirzoeva O.K., Calder P.C. The effect of propolis and its components on eicosanoid production during the inflammatory response. Prostaglandins Leukot. Essent. Fat. Acids 1996, 55:441-449. 10.1016/S0952-3278(96)90129-5.
16. Mutsaers H.A.M., Stribos E.G.D., Glorieux G., Vanholder R., Olinga P. Chronic kidney disease and fibrosis: the role of uremic retention solutes. Front. Med. 2015, 2:1-7. 10.3389/fmed.2015.00060.
17. Nakazawa T., Ohsawa K. Metabolism of rosmarinic acid in rats. J. Nat. Prod. 1998, 61:993-996. 10.1021/np980072s.
18. Nakazawa T., Ohsawa K. Metabolites of orally administere Perilla frutescens extract in rats and humans. Biol. Pharm. Bull. 1999, 23:122-127.
19. Petersen M., Simmonds M.S.J. Rosmarinic acid. Phytochemistry 2003, 62:121-125.
20. Pham B.T., et al. Precision-cut rat, mouse, and human intestinal slices as novel models for the early-onset of intestinal fibrosis. Physiol. Rep. 2015, 3:e12323. 10.14814/phy2.12323.
21. Poynard T., et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol. 2010, 10:40. 10.1186/1471-230X-10-40.
22. Rieder F., Brenmoehl J., Leeb S., Scholmerich J., Rogler G. Wound healing and fibrosis in intestinal disease. Gut 2007, 56:130-139. 10.1136/gut.2006.090456.
23. Rocha J., et al. Anti-inflammatory effect of rosmarinic acid and an extract of Rosmarinus officinalis in rat models of local and systemic inflammation. Basic Clin. Pharmacol. Toxicol. 2015, 116:398-413. 10.1111/bcpt.12335.
24. Sanbongi C. Rosmarinic acid inhibits lung injury induced by diesel exhaust particles. Free Radic. Biol. Med. 2003, 34:1060-1069. 10.1016/S0891-5849(03)00040-6.
25. Scheckel K.a., Degner S.C., Romagnolo D.F. Rosmarinic acid antagonizes activator protein-1-dependent activation of cyclooxygenase-2 expression in human cancer. J. Nutr. 2008, 2098-2107. 10.3945/jn.108.090431.
26. Torok N.J., Dranoff J.A., Schuppan D., Friedman S.L. Strategies and endpoints of antifibrotic drug trials: summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. Hepatology 2015, 62:627-634. 10.1002/hep.27720.
27. Wang L., et al. IL-6 induces NF-B activation in the intestinal epithelia. J. Immunol. 2003, 171:3194-3201. 10.4049/jimmunol.171.6.3194.
28. Westra I.M., Pham B.T., Groothuis G.M.M., Olinga P. Evaluation of fibrosis in precision-cut tissue slices. Xenobiotica 2012.
29. Westra I.M., Oosterhuis D., Groothuis G.M.M., Olinga P. Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs. Toxicol. Appl. Pharmacol. 2014, 274:328-338. 10.1016/j.taap.2013.11.017.
30. Westra I.M., Hadi M., Oosterhuis D., de Jong K.P., Groothuis G.M.M., Olinga P. Precision-cut liver slices an ex vivo model for the early onset and end-stage of liver fibrosis 2014, (134 pp.).
31. Wynn T., Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin. Liver Dis. 2010, 30:245-257. 10.1055/s-0030-1255354.
32. Xavier C.P.R., Lima C.F., Fernandes-Ferreira M., Pereira-Wilson C. Salvia fruticosa, Salvia officinalis, and rosmarinic acid induce apoptosis and inhibit proliferation of human colorectal cell lines: the role in MAPK/ERK pathway. Nutr. Cancer 2009, 61:564-571. 10.1080/01635580802710733.